Anastrozole Tablet
Product Images NDC 68071-3999

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 68071-3999). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3999 3)

Label for Anastrozole 1 mg tablets from NuCare Pharmaceuticals, Inc. The label indicates a package of 30 tablets for oral use with product number R1484030 and NDC 68071-3999-3. It includes storage instructions to keep the product at controlled temperature 68-77°F and a warning to keep out of reach of children, along with barcode and lot/serial number information.*

FDA Label Image

7b4ba0c5 0287 B7a7 E053 2991aa0a575e

An image of two round, white oral tablets of Anastrozole 1 mg. One tablet is marked with the imprint 'YL' and the other with '111'. These tablets are part of NuCare Pharmaceuticals, Inc.'s product line.*

FDA Label Image

Avet Logo (Avet)

FDA Label Image

Chemical Structure For Anastrozole (Image 01)

Chemical structure of Anastrozole, showing its molecular arrangement with aromatic and nitrogen-containing rings.*

FDA Label Image

Figure 1 (Image 02)

A line graph showing disease-free survival in months on the x-axis versus the proportion alive and disease-free on the y-axis. It compares two randomized treatments, anastrozole (dashed line) and tamoxifen (solid line), over approximately 90 months. Below the graph is a table indicating the number of patients at risk for each treatment group at various time points.*

FDA Label Image

Figure 2 (Image 03)

A survival curve chart showing disease-free survival over time in months for patients treated with anastrozole versus tamoxifen. The y-axis represents the proportion of patients alive and disease-free, and the x-axis shows time in months up to 90. The graph includes the number of patients at risk for both treatments at various time points.*

FDA Label Image

Figure 3 (Image 04)

Kaplan-Meier survival curves comparing Anastrozole and Tamoxifen treatments over 120 months. The graph shows proportion event-free on the y-axis and time to event in months on the x-axis. A patient risk table below indicates declining numbers of patients at various time points for each treatment group.*

FDA Label Image

Figure 4 (Image 05)

A Kaplan-Meier survival curve graph showing the proportion of patients event-free over time in months for two randomized treatments: Anastrozole and Tamoxifen. The graph includes a table with the number of patients at risk at various months up to 120 months.*

FDA Label Image

Figure 5 (Image 06)

A Kaplan-Meier curve comparing time to progression in months for patients treated with Anastrozole versus Tamoxifen. The y-axis represents the proportion of patients not progressing, while the x-axis shows time in months. The solid line corresponds to Anastrozole treatment and the dashed line corresponds to Tamoxifen treatment, with a numerical table of patient at-risk counts shown below.*

FDA Label Image

Figure 6 (Image 07)

A line graph comparing the proportion of patients not progressing between Anastrozole and Tamoxifen treatments over time in months. The x-axis shows time to progression up to 42 months, and the y-axis shows the proportion not progressing from 0 to 1. The graph includes a legend distinguishing Anastrozole (solid line) from Tamoxifen (dashed line), with patient risk numbers indicated below the timeline.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.